People dropped out of Eli Lilly’s new GLP-1 drug trial because they lost too much weight
Too much of a good thing? Participants taking the highest dose of Eli Lilly’s new GLP-1 drug lost an average of 28.7% of their body weight in a late-stage trial, putting it on track to be a heavyweight in the crowded world of weight-loss and diabetes treatments. But in a surprising twist, top-line results show … Read more